Incyte (INCY) PT Raised to $77 at RBC Capital; 'Base Case'

Incyte (INCY) Announces Expanded Clinical Collaboration with Immunovaccine Inc. to Evaluate Combination Immunotherapies in Advanced Recurrent Ovarian Cancer

Immunovaccine Inc. today announced that it has entered into an agreement with Incyte Corporation (NASDAQ: INCY) to expand their ongoing clinical trial collaboration. The Companies plan to add a Phase 2 component to their ongoing Phase 1b combination study evaluating the safety and efficacy of Immunovaccines lead candidate, DXP-Survivac, in combination with Incytes IDO1 enzyme inhibitor epacadostat and low dose cyclophosphamide in advanced ovarian cancer patients.

The Phase 2 component will be a randomized, open label, efficacy study that will include up to 32 additional evaluable subjects. It will evaluate DPX-Survivac and low dose cyclophosphamide... More

Eli Lilly & Co. (LLY) & Incyte Corporation (INCY) Confirms FDA Advisory Committee Recommends Approval of Baricitinib 2mg and Against 4mg

Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announced today that the U.S. Food and Drug Administration's (FDA) Arthritis Advisory Committee recommended approval of the 2-mg dose of baricitinib, a once-daily oral medication for the treatment of moderately-to-severely active rheumatoid arthritis (RA) for adult patients who have had an inadequate response or intolerance to methotrexate. While the Advisory Committee unanimously supported the efficacy of the 4-mg dose of baricitinib, it did not recommend approval of the 4-mg dose of baricitinib for the proposed... More

Incyte (INCY) PT Lowered to $75 at SunTrust Robinson Humphrey

SunTrust Robinson Humphrey lowered its price target on Incyte (NASDAQ: INCY) to $75.00 (from $80.00) while maintaining a Buy rating.

FDA Votes 10-5 to Back Incyte (INCY) and Lilly's (LLY) Baricitinib 2 mg, Votes 5-10 Against 4 mg

FDA Votes 10-5 to Back Incyte (NASDAQ: INCY) and Lilly's (NYSE: LLY) Baricitinib 2 mg, Votes 5-10 Against 4 mg

Incyte (INCY), Lilly (LLY) Low Dose Baricitinib Wins FDA Panel Vote on Safety; High Does Fails to Win Panel Vote on Safety - Bloomberg

Incyte (NASDAQ: INCY), Lilly (NYSE: LLY) Low Dose Baricitinib Wins FDA Panel Vote on Safety; High Does Fails to Win Panel Vote on Safety - Bloomberg